regulatory status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-11. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
== Romería de Torrijos festival == On the second Sunday of October there is a public holiday in the town, called "Romería de Torrijos". In 1923, the decision was taken to establish a pilgrimage to the sanctuary of Torrijos on the second Sunday of October, carrying in procession the image of the patroness. The Virgin is accompanied by numerous pilgrims in decorated carriages or on horseback. When the Virgin arrives at the Torrijos Hacienda, mass is celebrated in the central courtyard. It is a major pilgrimage of the Aljarafe comarca.
==== Overuse injuries ==== An overuse injury occurs when a certain activity is repeated frequently and the body does not have enough time to recover between occurrences. Examples include bursitis and tendinitis.
{\displaystyle {\frac {\mathrm {d} \left[\mathrm {M} _{1}\right]}{\mathrm {d} \left[\mathrm {M} _{2}\right]}}={\frac {\left[\mathrm {M} _{1}\right]\left(r_{1}\left[\mathrm {M} _{1}\right]+\left[\mathrm {M} _{2}\right]\right)}{\left[\mathrm {M} _{2}\right]\left(\left[\mathrm {M} _{1}\right]+r_{2}\left[\mathrm {M} _{2}\right]\right)}}}
Sources: en.wikipedia.org
Mouse MA-10 cells respond to 5-oxo-ETE but lack OXER1. It has been suggested that these cells' responses to 5-oxo-ETE are mediated by an ortholog to OXER1, mouse niacin receptor 1, Niacr1, which is a G protein-coupled receptor for niacin, or, alternatively, by one or more of the mouse hydroxycarboxylic acid (HCA) family of the G protein-coupled receptors, HCA1 (GPR81), HCA2 (GPR109A), and HCA3 (GPR109B), which are G protein-coupled receptors for fatty acids.
When genotypes grown together in a diverse population have different profiles of resource use they complement each other in the exploitation of the limiting resource and therefore are subject to smaller between-plant competition. In case of disease or environmental change some plants will take over when others fail. Yield stability over years and environments can be better than pure lines due to compensation. Participatory plant breeding (PPB) methods represent alternatives aimed to improve local adaptation breeding, to promote genetic diversity, to empower farmers and rural communities. In PPB farmers are actively participating in developing new cultivars or populations, e.g. by performing selection.
The nobelium can then be isolated by exploiting its tendency to form the divalent state, unlike the other trivalent actinides: under typically used elution conditions (bis-(2-ethylhexyl) phosphoric acid (HDEHP) as stationary organic phase and 0.05 M hydrochloric acid as mobile aqueous phase, or using 3 M hydrochloric acid as an eluant from cation-exchange resin columns), nobelium will pass through the column and elute while the other trivalent actinides remain on the column. However, if a direct "catcher" gold foil is used, the process is complicated by the need to separate out the gold using anion-exchange chromatography before isolating the nobelium by elution from chromatographic extraction columns using HDEHP.
Sources: en.wikipedia.org
Basophil Basophils exhibit large, dark purple granules that often cover the cell's nucleus. They are the rarest of the five normal cell types. Basophilia and eosinophilia can occur along with other white blood cell abnormalities in chronic myeloid leukaemia and other myeloproliferative disorders. An increased basophil count may also be seen in hypersensitivity reactions and after splenectomy. The basophil count may decrease during ovulation, steroid treatment, and periods of physiological stress.
== Mechanism of action == Difenoxin has a high peripheral/central actions ratio, working primarily on various opioid receptors in the intestines. Although it is capable of producing significant central effects at high doses, doses within the normal therapeutic range generally do not notably impair cognition or proprioception, resulting in therapeutic activity roughly equatable to that of loperamide (Imodium). Increased dosages result in more prominent central opioid effects (and anticholingeric effects when the formulation also contains a tropane alkaloid). It therefore offers limited advantages over more potent anti-diarrheal opioid options (ex. morphine) when treating intractable cases of diarrhea which fail to respond to normal or moderately increased difenoxin doses, and may in fact be harmful in such circumstances if the formulation used also contains atropine or hyoscyamine.
== Society and culture == VVMs are made by Zebra Technologies and are derived from their "HEATmarker" products. Zebra holds a patent on the VVM+. Temptime Corporation, which Zebra purchased in 2019, holds multiple patents on HEATmarker; these are cited in the VVM+ patent.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.